Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice Find.
Funny how one investor of Woodfords stature can open doors, and position you in the right place at the right time. This may be a lot bigger than we now realize.
Cryoport moving to new offices in the future?
From the original S1:
DESCRIPTION OF PROPERTY
We do not own real property. We currently lease one facility, with approximately 12,000 square feet of corporate, research and development, and warehouse facilities, located in Lake Forest, California under an operating lease expiring June 30, 2015, which we do not intend to renew. We are currently exploring other facilities to meet our growing demands.
From the most recent S1:
The Company currently makes base lease payments of approximately $10,000 per month, due at the beginning of each month. We believe that these facilities are adequate, suitable and of sufficient capacity to support our immediate needs. Additional space may be required, however, as we expand our research and development, manufacturing and selling and marketing activities.
The operating lease obligations are primarily related to the facility lease for our principal executive office in Lake Forest, California, which expires June 30, 2015. In May 2015, we amended the lease to convert to a month-to-month basis, commencing July 1, 2015. The base rent will be $9,500 and either party will have the right to cancel this month-to-month agreement by giving the other party a minimum of a 90-day prior written notice. We also lease certain office equipment.
With the recent articles found by Stockwatchman, it does seem this space in the logistics market is growing quite rapidly. This is an excerpt from the S1. It appears that this is true, and as Ice pointed out earlier, CYRX is planning on going after the whole dry ice market.
From the S1:
Cryoport’s Positioning in the Life Sciences Industry
Life sciences technologies are expected to have a significant impact on global society over the next 25 years. In the United States alone, the life sciences industry is made up of 6,000 identifiable establishments. However, the industry is growing globally in a way where research and manufacturing pipelines span across the globe, which increases the need to mitigate logistics risk.
The total cold chain logistics market has historically grown 70% faster per annum than the total logistics market. For 2011, global cold chain logistics transportation costs were reported to be $7.2 billion; about $1.5 billion within the cryogenic range of requirements. By 2017, transportation cost alone, for global life sciences cold chain logistics, is forecasted to grow to $9.3 billion, a 41% increase, and twice the growth of the overall market.
In addition, with the recent advancements in the development of biologics and cell-based therapies, scientists, intermediaries, and manufacturers require the means for cryogenically transporting their work. Temperatures must be maintained below the “glass point” (generally, minus 136°C) while shipping these therapies to ensure that the shipped specimens are not subject to degradation that could impact its characteristics and efficacy.
While we estimate that our solutions currently offer comprehensive and technology-based monitoring and tracking for a potential of six to seven million deep frozen shipments globally on an annual basis, we also believe that with investment in our services, adaptations of our solutions can be applied to a large portion of an additional fifty-five to sixty million annual shipments requiring ambient (between 20° and 25°C), chilled (between 2° and 8°C) or frozen (minus 10°C or less) temperatures.
Cryoport’s clients include companies and institutions that require reliable cryogenic logistics solutions such as therapy developers for personalized medicine, bio-pharmaceuticals, research, contract research organizations, diagnostic laboratories, contract manufacturers, cord blood repositories, vaccine manufacturers, animal husbandry related companies, and in-vitro fertilization clinics.
Nice find, Thanks
Seem the shorts have a hold of it, and are really hoping for another capital raise. A nice PR from the company would go a long way. Shorts need to have their lunch handed to them.
It seems we lose the "D" today.
They have to tell you if you call and ask.
Fidelity told me that any shares in a IRA are not eligible to be loaned for shorting purposes.
Immunotherapy
I do not think anyone here is saying that immunotherapy will add millions to the bottom line in the next few quarters. What we are saying is that it is the hottest sector in oncology. It has been estimated that over 50 percent of the newly approved drugs will need cryopreservation.
One example is Northwest Biotherapeutics. They have a phase 3 study in GBM which will yield top line results next year. If you are not familiar with the GBM market, the new therapy pipeline has been miserable for 30 years. If this should become SOC, which is a very real possibility, this could mean 40,000 shipment per year in the US alone.
http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/brain-cancer
A randomized, placebo-controlled phase III trial testing DCVax-L, a dendritic cell vaccine derived from a patient’s own tumor, for newly diagnosed glioma (including glioblastoma/glioblastoma multiforme and astrocytoma) (NCT00045968). - See more at: http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/brain-cancer#sthash.4Jpt6x9L.dpuf
This says nothing of DcVax Direct, which is used for all inoperable solid tumors. Direct has just reported stellar Phase 1 results at ASCO, and is now formulating a Phase 2 Trial.
The revenue generating possibilities are real, and they are in the foreseeable future.
That report cannot be as negative as your posts. I am sure you will share nothing positive with this board about the company, because at this point it is not in your best interest to do this, and you know what I mean.
I have a free membership. If you can PM me, give me your email and we can correspond. If not, I thought there was something called happy hour on Friday afternoon, where you can PM other members even if you have a free account. Not quite sure how that works, or if it still does. If it does we can exchange emails that way.
I agree 100% with your analysis here.
Ice,
I think you are right, you SW and myself are the only ones who really get it. The rest can't come to the realization of how inept and crooked Stambaugh was. They also cannot come to the realization that there was nothing wrong with the product, it was all in the execution. You either believe or you remain bitter. If you are the latter, why punish yourself any longer. Just move on. I look forward to getting this capital raise behind us,and moving forward. The immunotherapy market awaits, and Cryoport is ready. I guess I need to get my cheerleader uniform back from the cleaners...LOLOL
Continuing from the 10-K
We are continuing our research and development efforts to further refine our current technology as well as explore opportunities with partners to offer complementary packaging solutions for frozen temperature (minus 10° Celsius or less), chilled temperature (2° to 8° Celsius) and ambient temperature (between 20° and 25° Celsius) shipping market
As for the money, I went to the Cryoport building in Lake Forest last year. It is a small building, which I would think this business will blow the roof of it. My wife even commented that "This doesn't look like much," which was exactly what I wanted to see last year. No frills. They have stated they are going to upgrade the Cryoportal software, and they will probably at least need to double or triple their dewar fleet. This will all take money. Additionally, large Pharma will not give you their business if they think you might go belly up in the near future. They need the money, they have been running on fumes too long!
Maybe this will help....
"The growth for the year was driven by a diverse base of new and expanding client relationships and a further increase in our IVF business. Most of these clients are either in the early stages of their product development or in the early stages of introducing our solutions to their operations. We view this as 'built in' growth as there are significant opportunities for these relationships to expand over time. Many of these companies are in exciting market segments that are experiencing significant growth, such as CAR-T Cells, stem cells, cell therapies, cell line manufacturing, research, and vaccines, as well as animal husbandry and in vitro fertilization (IVF). In addition, our support of clinical trials is also developing in all segments and across all regions. In fact, as of the end of the fourth quarter, Cryoport was actively supporting the logistics needs for 34 clinical trials including six phase III programs."
Double Ditto
Agree on all points made. I am also looking forward to the 4th quarter numbers, but I think I look to the guidance coming after at the conference. The reverse is at this point a necessary evil. I have been through a few of these, but never with the company doing the reverse having such momentum. This next year, I think will be Great!
Interesting Article on "Liquid Biopsies."
http://news.yahoo.com/blood-tests-liquid-biopsies-may-transform-cancer-care-070149646.html;_ylt=AwrBT9QJ_1BVvJUAtp5XNyoA;_ylu=X3oDMTEzaTduOW
I would think it will be just like a conference call. You release your annual and quarterly report an hour before the conference. Then, you use the conference setting to discuss it. Very bullish in my opinion. Remember, they technically have until the end of June to file this report. This is coming early, to bolster the share price before the S1 is completed, I think.
I would read this as the offering thru Emergent Financial was oversubscribed and they authorized more Preferred B stock for this offering. Someone correct me if I am wrong, please.
I believe they are released around April 20. Last year Northwest PR'ed their abstract around this release time. I was thinking it was suspect to say their was no abstract this year, as we just don't know yet.
http://am.asco.org/abstracts
How Cryoport executes is the key. They have a lot of wind at their backs. I do believe this management can execute. They have taken us from ashes without a lot of money. I am a believer.
This post, like you, is irrelevant. Go argue with someone who believes what you say, if you can find anyone. You, sir, are losing it.
That you don't think you need credibility is quite obvious to all. Just wonder what you will argue next week or next month. Or on what side? I guess it doesn't matter to you if your argument is true or not. You need credibility for people to believe your position. If you argue without credibility, it makes you irrelevant.
I was reading a Zacks Research Report from August 2012. It seems all the major carriers were trying to go it alone in the cryogenic shipping space. In 2 years they had all signed with Cryoport. It tells me Cryoport has the best service, and as soon as one signed, the others did not want to be left behind in the immunotherapy revolution. We are witnessinig just the beginning of this revolution, and it all demands cryogenic temperatures, and there is no second chance to ship it again, if there is a problem in transit!
SPECIALTY LOGISTICS
The other side of the competitive spectrum is the service side of the business this comes mostly from specialty
logistics organizations. World Courier is the largest specialty courier service for the pharmaceutical industry the
company claims that they are involved in transportation and logistics with 80% of the world s clinical trials which
require specialty courier service. The company has over 140 offices throughout the world and offers
comprehensive clinical trial services including transportation scheduling from collection site to lab, expertise in
cold chain handling, dry ice replenishment, shipment monitoring with real-time tracking and customs clearance.
The company offers a proprietary clinical trials data management system which can, according to World Courier,
take clinical trial logistics management to an entirely new level and can proactively anticipate and prevent costly
transportation problems that are so often unavoidable when conducting studies .
CryoPort acknowledges that these specialty carriers offer a competitive threat but due to the relatively high cost of
these service providers, that CryoPort s system can provide a cheaper alternative with no compromise to service,
ease or convenience. In their recent investor presentation, CryoPort noted that a study done by Quest Diagnostics
showed that CryoPort s Express Shipping system cost approximately 20% less than compared to World Courier in
shipping to 21 Asian cities.
With the recent surge in cold chain shipping demand, large air carriers have been launching their own specialty
pharmaceutical shipping services. Pharmaceutical Commerce notes that in less than three years time the number
of airlines launching pharmaceutical product offerings has grown from four to more than a dozen. Some of these
include
American Airlines recently teamed up with Envirotainer, a manufacturer of large cold chain shipping
containers, in launching their ExpediteTC service which is focused on temperature-controlled shipping.
DHL and Lufthansa created a joint venture called LifeConEx which provides an all-inclusive pricing and
delivery system for temperature-sensitive biopharma products and with a specified, pre-validated container
whose delivery and return to LifeConEx takes responsibility for. LifeConEx has also announced an oceandelivery
service for life sciences, brandnamed H2Cargo .
UPS just launched its UPS Healthcare Logistics service with a focus on distribution, logistics and
transportation of pharmaceutical products including cold chain services.
FedEx Custom Critical is an expedited (same day or overnight) air shipping service which includes
temperature controlled products, handling and transportation. FedEx also recently rolled out its SenseAware
tracking device in 2010. The device, in real time, monitors the location and temperature of packages. FedEx
offers both the tracking device and related software to customers. FedEx s agreement with CryoPort, which
FedEx markets as FedEx Deep Frozen Shipping Solution, is part of the carriers FedEx Healthcare Solutions business.
Myself, I have never seen a more "shareholder friendly" management.
They probably could have raised 10 million last year at .20, but did not. They are trying to protect the little guy, while moving the product forward. The biggest mistake here was giving the keys to Larry Stambaugh and his board of directors. They are really the ones who screwed you, not Jerrell Shelton, Rathman, etc. The real turn is when they elected Wasserman to the board. He put this team together, and should be given a lot more credit than he gets!
Thank you...
I guess I want the data faster than they are giving it...LOLOL
I guess some here have forgotten the real Cramer....
This guy is nothing but a Crook, plain and simple.
Don't quite see how anyone can defend him in any way.
Agreed. There is no way Cramer does not screen these calls. Something is afoot and Cramer is covering his you know what.
Sorry RK,
What he wrote to you is balderdash. Doesn't mean he didn't sell his shares at all. Sounds like he is dancing around the question. Maybe in your next PM ask him if he did. Maybe, and it's a big maybe, he will tell you the truth.
Ps. I am awake too, and I have all my shares.
My $.02
Interesting take on events, RK.
Thank You!
BRAVO...
Outstanding work as usual Senti, and Thank You!
Double Ditto.
Seems according to the Squid's article, this looks like real Compassionate Use to me:
It is a weak argument because as the article states these drugs have been approved by the FDA and DCVax is not. These FDA approvals may have carried more weight with the PIM decision.